Literature DB >> 16569846

Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole.

A Lepak1, J Nett, L Lincoln, K Marchillo, D Andes.   

Abstract

Pharmacodynamics (PD) considers the relationship between drug exposure and effect. The two factors that have been used to distinguish the PD behaviors of antimicrobials are the impact of concentration on the extent of organism killing and the duration of persistent microbiologic suppression (postantibiotic effect). The goals of these studies were (i) to examine the relationship between antimicrobial PD and gene expression and (ii) to gain insight into the mechanism of fluconazole effects persisting following exposure. Microarrays were used to estimate the transcriptional response of Candida albicans to a supra-MIC F exposure over time in vitro. Fluconazole at four times the MIC was added to a log-phase C. albicans culture, and cells were collected to determine viable growth and for microarray analyses. We identified differential expression of 18% of all genes for at least one of the time points. More genes were upregulated (n=1,053 [16%]) than downregulated (174 [3%]). Of genes with known function that were upregulated during exposure, most were related to plasma membrane/cell wall synthesis (18%), stress responses (7%), and metabolism (6%). The categories of downregulated genes during exposure included protein synthesis (15%), DNA synthesis/repair (7%), and transport (7%) genes. The majority of genes identified at the postexposure time points were from the protein (17%) and DNA (7%) synthesis categories. In subsequent studies, three genes (CDR1, CDR2, and ERG11) were examined in greater detail (more concentration and time points) following fluconazole exposure in vitro and in vivo. Expression levels from the in vitro and in vivo studies were congruent. CDR1 and CDR2 transcripts were reduced during in vitro fluconazole exposure and during supra-MIC exposure in vivo. However, in the postexposure period, the mRNA abundance of both pumps increased. ERG11 expression increased during exposure and fell in the postexposure period. The expression of the three genes responded in a dose-dependent manner. In sum, the microarray data obtained during and following fluconazole exposure identified genes both known and unknown to be affected by this drug class. The expanded in vitro and in vivo expression data set underscores the importance of considering the time course of exposure in pharmacogenomic investigations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569846      PMCID: PMC1426956          DOI: 10.1128/AAC.50.4.1311-1319.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

2.  A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site.

Authors:  D Andes; A Lepak; A Pitula; K Marchillo; J Clark
Journal:  J Infect Dis       Date:  2005-07-25       Impact factor: 5.226

3.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

4.  Characteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry.

Authors:  M Gottfredsson; H Erlendsdóttir; A Sigfússon; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Authors:  A Louie; G L Drusano; P Banerjee; Q F Liu; W Liu; P Kaw; M Shayegani; H Taber; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

7.  Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

9.  Effects of sublethal concentrations of amphotericin B on Candida albicans.

Authors:  K M Nugent; K R Couchot
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

10.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.

Authors:  K J Livak; S J Flood; J Marmaro; W Giusti; K Deetz
Journal:  PCR Methods Appl       Date:  1995-06
View more
  19 in total

1.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  Fungal Biofilms: Relevance in the Setting of Human Disease.

Authors:  Luis R Martinez; Bettina C Fries
Journal:  Curr Fungal Infect Rep       Date:  2010-12-01

3.  A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.

Authors:  Jeongmi Kim; Yong-Joon Cho; Eunsoo Do; Jaehyuk Choi; Guanggan Hu; Brigitte Cadieux; Jongsik Chun; Younghoon Lee; James W Kronstad; Won Hee Jung
Journal:  Fungal Genet Biol       Date:  2012-09-04       Impact factor: 3.495

Review 4.  Pathogenesis of Candida albicans biofilm.

Authors:  Christina Tsui; Eric F Kong; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2016-06       Impact factor: 3.166

5.  Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.

Authors:  Ranjith Rajendran; Eilidh Mowat; Elaine McCulloch; David F Lappin; Brian Jones; Sue Lang; Jayesh B Majithiya; Peter Warn; Craig Williams; Gordon Ramage
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

6.  Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence.

Authors:  Elias Epp; Ghyslaine Vanier; Doreen Harcus; Anna Y Lee; Gregor Jansen; Michael Hallett; Don C Sheppard; David Y Thomas; Carol A Munro; Alaka Mullick; Malcolm Whiteway
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

7.  Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering.

Authors:  Dwight Kuo; Kai Tan; Guy Zinman; Timothy Ravasi; Ziv Bar-Joseph; Trey Ideker
Journal:  Genome Biol       Date:  2010-07-23       Impact factor: 13.583

8.  Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis.

Authors:  Alessandro Fiori; Patrick Van Dijck
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

9.  Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans.

Authors:  Adnane Sellam; Faïza Tebbji; André Nantel
Journal:  Eukaryot Cell       Date:  2009-06-19

10.  Time course global gene expression analysis of an in vivo Candida biofilm.

Authors:  Jeniel E Nett; Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.